Pfizer’s exit acts as a "clearing of the deck" —it removes a conflicting Big Pharma voice, leaving the GSK-Shionogi-ViiV Triad as a streamlined unit ready to ingest the Leronlimab asset.This is no longer just a "small cap" story; it is a Corporate Interchange where Leronlimab serves as the common denominator between an HIV Cure and an Oncology revolution.
I appreciate the board’s feedback on my 'branding.' I use these terms to simplify the massive corporate and clinical shifts happening right now. To ensure we aren't talking past each other, here is a dictionary for the May 2026 Scoreboard:
The Search Warrant: This is the 88% PD-L1 Upregulation data. It’s the proof that Leronlimab forces tumors to show a 'Neon Sign' so the Immune System's Killer Cells can find and destroy them.
Molecular Sweep: When a drug cleans out the 'shield' cells (Macrophages and Tregs) which protect a Tumor from those Killer Cells.
Universal Backbone: A drug like Leronlimab that can be paired with any other therapy to make it work better.
The 700mg Mandate: In my opinion, once the DSMB clears safety, the 350mg 'lightweight' arm is abandoned. 700mg becomes the Sovereign Dose—the Sledgehammer needed to reach that 88% upregulation.
Leaked Prospectus: I was referencing your previous comment about needing one, as if GSK was writing a letter of intent; my point is that the $1.9B Pfizer exit and Max Lataillade’s move is the prospectus written in plain sight.
The GSK-Shionogi-ViiV Triad:These companies work in a 'Corporate Interchange.' ViiV is the HIV specialist, while GSK and Shionogi (the parents) are the Oncology giants.
HIV (The Floor): Scott Hansen’s Non-Human Primate (Macaque) models have already shown that Leronlimab can stabilize CCR5 for months, 6 or more. By using 'Receptor Occupancy' assays, he proved that Leronlimab anchors the receptor so tightly that it could replace Maraviroc as the 'Gold Standard' for Salvage Therapy (patients who have failed all other drugs).
Oncology (The Ceiling): Leronlimab is the Prime in 'Prime & Pair.' It turns 'Cold' tumors 'Hot' by itself, but when Paired with Shionogi’s drug (S-531011) and GSK’s Jemperli, it becomes a Triple Threat.
Shionogi’s ASCO 2025 data specifically showed their best results in Colorectal Cancer (CRC)—the exact target of our 700mg trial.
Partnership vs. Buyout:In my opinion, a buyout right now might not hit the $60 Billion mark. But a Strategic Partnership first acts as a stepping stone. It validates the 88% Upregulation, drives the share price up, and makes that $60B valuation a reality for Merck or GSK later.
Scott Hansen’s NHP Models: Dr. Scott Hansen’s work is the "Silent Prospectus" for ViiV. His Non-Human Primate (NHP) models showed:6-Month Stability, we've seen and talked about it: While we currently talk about weekly doses, his data on Receptor Occupancy (RO) suggests that Long Acting Leronlimab’s binding is so "sticky" that it could potentially protect cells for up to 6 months or more.
Salvage Efficacy: In "salvage" scenarios where HIV has mutated against other drugs, Leronlimab’s unique binding site remains effective because it targets the host cell, not the virus.
The Merck Consideration: Merck is watching the 700mg Mandate because the 88% PD-L1 Upregulation is a "Patent Life Extender." If Keytruda (facing a 2028 cliff) is paired with Leronlimab as a "New Combination Therapy," Merck can effectively reset the clock on their multi-billion dollar revenue stream.
All in my opinion.
I appreciate the board’s feedback on my 'branding.' I use these terms to simplify the massive corporate and clinical shifts happening right now. To ensure we aren't talking past each other, here is a dictionary for the May 2026 Scoreboard:
The Search Warrant: This is the 88% PD-L1 Upregulation data. It’s the proof that Leronlimab forces tumors to show a 'Neon Sign' so the Immune System's Killer Cells can find and destroy them.
Molecular Sweep: When a drug cleans out the 'shield' cells (Macrophages and Tregs) which protect a Tumor from those Killer Cells.
Universal Backbone: A drug like Leronlimab that can be paired with any other therapy to make it work better.
The 700mg Mandate: In my opinion, once the DSMB clears safety, the 350mg 'lightweight' arm is abandoned. 700mg becomes the Sovereign Dose—the Sledgehammer needed to reach that 88% upregulation.
Leaked Prospectus: I was referencing your previous comment about needing one, as if GSK was writing a letter of intent; my point is that the $1.9B Pfizer exit and Max Lataillade’s move is the prospectus written in plain sight.
The GSK-Shionogi-ViiV Triad:These companies work in a 'Corporate Interchange.' ViiV is the HIV specialist, while GSK and Shionogi (the parents) are the Oncology giants.
HIV (The Floor): Scott Hansen’s Non-Human Primate (Macaque) models have already shown that Leronlimab can stabilize CCR5 for months, 6 or more. By using 'Receptor Occupancy' assays, he proved that Leronlimab anchors the receptor so tightly that it could replace Maraviroc as the 'Gold Standard' for Salvage Therapy (patients who have failed all other drugs).
Oncology (The Ceiling): Leronlimab is the Prime in 'Prime & Pair.' It turns 'Cold' tumors 'Hot' by itself, but when Paired with Shionogi’s drug (S-531011) and GSK’s Jemperli, it becomes a Triple Threat.
Shionogi’s ASCO 2025 data specifically showed their best results in Colorectal Cancer (CRC)—the exact target of our 700mg trial.
Partnership vs. Buyout:In my opinion, a buyout right now might not hit the $60 Billion mark. But a Strategic Partnership first acts as a stepping stone. It validates the 88% Upregulation, drives the share price up, and makes that $60B valuation a reality for Merck or GSK later.
Scott Hansen’s NHP Models: Dr. Scott Hansen’s work is the "Silent Prospectus" for ViiV. His Non-Human Primate (NHP) models showed:6-Month Stability, we've seen and talked about it: While we currently talk about weekly doses, his data on Receptor Occupancy (RO) suggests that Long Acting Leronlimab’s binding is so "sticky" that it could potentially protect cells for up to 6 months or more.
Salvage Efficacy: In "salvage" scenarios where HIV has mutated against other drugs, Leronlimab’s unique binding site remains effective because it targets the host cell, not the virus.
The Merck Consideration: Merck is watching the 700mg Mandate because the 88% PD-L1 Upregulation is a "Patent Life Extender." If Keytruda (facing a 2028 cliff) is paired with Leronlimab as a "New Combination Therapy," Merck can effectively reset the clock on their multi-billion dollar revenue stream.
All in my opinion.
3
1
